ADU-1805

ADU-1805 binds to hSIRPαV1 with a K_d value of 11.0 × 10^-9 M, and exhibits binding properties similar to those of the parental and chimeric hSIRPα.40A antibody variants^[1].
ADU-1805 potently binds to primary monocytes and neutrophils, while exhibits extremely weak binding to lymphocytes^[1].
ADU-1805 (0.67-66.7 nM; 2 h) promotes Rituximab (HY-P9913)-mediated phagocytosis of Raji Burkitt's lymphoma cells by peripheral blood-derived macrophages in a concentration-dependent manner^[1].
ADU-1805 (0.067-66.7 nM; 2 h) enhances Rituximab-mediated trogocytosis of primary neutrophils against BJAB Burkitt's lymphoma cells in a concentration-dependent manner^[1].
ADU-1805 does not bind to primary red blood cells or platelets, nor does it induce hemagglutination of red blood cells^[1].
ADU-1805 (5 days) neither inhibits T cell activation nor reduces T cell counts in allogeneic mixed lymphocyte reactions^[1].
ADU-1805 (100 μg/mL; 3 days) does not inhibit SEB-induced T cell activation and proliferation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.